- Home
- CISO vs AKTX Comparison
CISO vs AKTX Comparison
Compare CISO & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CISO
- AKTX
- Stock Information
- Founded
- CISO 2015
- AKTX N/A
- Country
- CISO United States
- AKTX United States
- Employees
- CISO N/A
- AKTX N/A
- Industry
- CISO Computer Software: Prepackaged Software
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- CISO Technology
- AKTX Health Care
- Exchange
- CISO Nasdaq
- AKTX Nasdaq
- Market Cap
- CISO 12.4M
- AKTX 24.5M
- IPO Year
- CISO N/A
- AKTX N/A
- Fundamental
- Price
- CISO $1.09
- AKTX $0.91
- Analyst Decision
- CISO
- AKTX
- Analyst Count
- CISO 0
- AKTX 0
- Target Price
- CISO N/A
- AKTX N/A
- AVG Volume (30 Days)
- CISO 401.5K
- AKTX 25.1K
- Earning Date
- CISO 04-15-2025
- AKTX 03-25-2025
- Dividend Yield
- CISO N/A
- AKTX N/A
- EPS Growth
- CISO N/A
- AKTX N/A
- EPS
- CISO N/A
- AKTX N/A
- Revenue
- CISO $54,633,909.00
- AKTX N/A
- Revenue This Year
- CISO $78.76
- AKTX N/A
- Revenue Next Year
- CISO N/A
- AKTX N/A
- P/E Ratio
- CISO N/A
- AKTX N/A
- Revenue Growth
- CISO 34.87
- AKTX N/A
- 52 Week Low
- CISO $0.26
- AKTX $0.85
- 52 Week High
- CISO $3.84
- AKTX $4.40
- Technical
- Relative Strength Index (RSI)
- CISO 50.35
- AKTX 41.35
- Support Level
- CISO $0.96
- AKTX $0.89
- Resistance Level
- CISO $1.10
- AKTX $1.00
- Average True Range (ATR)
- CISO 0.14
- AKTX 0.09
- MACD
- CISO 0.01
- AKTX 0.01
- Stochastic Oscillator
- CISO 54.15
- AKTX 22.27
About CISO CISO Global Inc.
CISO Global Inc provides cybersecurity services. The services are used to protect client's data, financial information, intellectual property, and business reputation. The services include penetration testing, security remediation, compliance auditing, vulnerability assessment, and others. Geographically, the company operates in U.S., Chile and All other countries. The maximum revenue is generated from U.S.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).